ArteraAI Prostate is now an FDA-regulated software (as a medical device) to estimate long-term outcomes and predict the benefit of hormone therapy for individual patients with localized prostate ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

Credit: Getty Images Large language models leverage transformed architecture to extract and summarize unstructured electronic health record data, enabling automated retrieval of clinically relevant ...

New research in JNCCN—Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated according to NCCN ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

An implantable microdevice safely delivered multiple drugs directly into prostate cancer lesions, enabling assessment of tumor-specific responses. All 14 patients successfully underwent robot-assisted ...